)
)
Our featured content
How Sibylla Biotech is using AI to solve the problem of non-druggable targets
Artificial Intelligence is revolutionising healthcare by automating tasks and enhancing diagnostics and treatments. Startups are particularly focusing on AI to tackle diseases caused by non-druggable proteins, which have long been a challenge in medicine. Sibylla Biotech, a Vi Partners portfolio company, is using machine learning to develop innovative treatments targeting these elusive proteins, potentially unlocking breakthroughs in biotech and pharmaceuticals. Learn more about the impact of AI on healthcare and how companies like Sibylla Biotech are leading the way in our latest blog post.
)
A coffee chat with Vincent Bieri, co-founder of Nexthink – Switzerland's fastest-growing SaaS unicorn
In a recent conversation with Vincent Bieri, co-founder of Nexthink, we discussed about his fascinating journey at the company.
)
Navigating your tech career, a Venture Capitalist’s perspective
Over the years of working as a venture capitalist, I have had the opportunity to connect with and advise many talented individuals within the entrepreneurial community, including experienced tech engineers. During my conversations with numerous talented software developers, I've noticed a common trend...
)
Exploring AI Agents: The Evolution from Chatbots to Intelligent Autonomous Systems
We recently had the chance to sit down with our friend and entrepreneur, Stelio Tzonis, to discuss the increasing role of Artificial Intelligence (AI) in venture capital in a context where reports show that AI now accounts for 25% of all U.S. venture investments. We discussed how the emergence of Large Language Models affects the stock market, evidenced by NVIDIA's skyrocketing value and the overall "hype" around AI technologies.
)
The most convenient & smart way to lease any car, anywhere - Why we invested in LeaseTeq
Vi Partners led the Series A round of LeaseTeq, a company on a mission to offer the world’s most convenient and smart way to lease any car, anywhere.
)
Venture Capital Market Evolution in 2023
2023 is behind us and what a year it was. Let’s review the year in digital healthcare investing and find out how much we achieved, despite the challenging environment.
)
Vi Partners announce a new CHF 8 Mio. Series A investment in LeaseTeq
Successful closing of Series A financing round LeaseTeq and Vi Partners are thrilled to announce the successful completion of a Series A financing round – a pivotal moment in the journey to redefine leasing through cutting-edge technology. With CHF 8m in a first closing and CHF 10m total round size.
)
Top Swiss Banks Embrace GenAI Transformation with Unique FinanceGPT
Unique AG, the Swiss-based AI-driven FinanceGPT company, announced an official go-live with their client Pictet Group. This rollout enables over 5,000 employees to experience the power of One.Chat, a platform co-developed together with Pictet that allows easy access to all internal information.
)
Study Published in Nature Digital Medicine Shows Potential Predictive Power of Augmented Reality-based Cognitive and Functional Assessment for Alzheimer’s Disease
Altoida announced today results from the RADAR-AD consortium study, published in Nature Digital Medicine, which evaluated its augmented reality (AR) and machine learning (ML)-based digital cognitive assessment for the early identification of individuals with Alzheimer’s Disease (AD).
)
Pushing Boundaries: Vi Partners CEO Day 2023
The Vi Partners CEO Day was a vibrant gathering of innovative minds and spirited discussions. We were honoured to host our portfolio companies' founders, our esteemed investors, and various key players from the ecosystem.
)
Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris’ Proprietary Linker-Conjugation Technology
Araris, the Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris will use its proprietary linker-conjugation platform to generate novel ADCs against undisclosed targets provided by Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma company with a focus on oncology.
)
JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints
The developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced results from the ALIGN-AR Pivotal Trial for the Trilogy THV System in high-risk patients with symptomatic, severe aortic regurgitation (AR).
)
Ninox introduces flexible CRM for SMBs based on low-code.
Leading Berlin-based software provider Ninox is setting a milestone in the world of business applications with the market launch of Ninox CRM. Thanks to low-code, the flexible and individually customizable complete solution allows the continuous digitization of processes on a single platform.
)
Unlocking Startup Potential: The Vi Partners 4Ps Blueprint
At Vi Partners, we're not just about crunching numbers; we're treasure hunters. What are we digging for? The future leaders of the B2B SaaS universe, particularly in Europe and Switzerland.
)
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing
Funding extends Xeltis’ Series D2 financing round to €44.5 million.
)
Oculis announce positive results from a Phase 3 OPTIMIZE trial showing that a daily does of OCS-01 eye drops treats inflammation and pain following cataract surgery
OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery Once daily OCS-01 meets primary endpoints demonstrating superior reduction in inflammation and pain vs. vehicle following cataract surgery OPTIMIZE’s results follow the positive and statistically significant top line results from stage 1 of the Phase 3 DIAMOND trial in Diabetic Macular Edema (DME) reported earlier this year, further highlighting the product’s potential for treating front- and back-of-the-eye diseases
)
Latest News
)
)
)
)
)
Entrepreneurs improve the world. We proudly support them.
Our heritage
Who we are and how we started
Vi Partners' founding team came together in 2000 to advise Venture Incubator, an investment vehicle initiated by ETHZ and funded by ten blue-chip Swiss companies. Today, we advise funds investing across Europe in tech and healthcare.
)